Skip to main content
Erschienen in: Endocrine 1/2013

01.02.2013 | Original Article

Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations

verfasst von: Marilena Celano, Marialuisa Sponziello, Giovanni Tallini, Valentina Maggisano, Rocco Bruno, Mariavittoria Dima, Enrico Di Oto, Adriano Redler, Cosimo Durante, Rosario Sacco, Sebastiano Filetti, Diego Russo

Erschienen in: Endocrine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Autonomously functioning thyroid nodules (AFTN) are known to receive an increased blood influx necessary to sustain their high rate of growth and hormone production. Here, we investigated the expression of hematic and lymphatic vases in a series of 20 AFTN compared with the contralateral non-tumor tissues of the same patients, and the transcript levels of proteins involved in the control of vascular proliferation, including the vascular endothelial growth factor (VEGF) and platelet-derived growth factors (PDGF) and their receptors and the endothelial nitric oxide synthase (eNOS). In parallel, the expression of the differentiation markers sodium/iodide symporter (NIS), thyroperoxidase (TPO), thyroglobulin (Tg), and TSH receptor (TSHR) was also investigated. The data were further analyzed comparing subgroups of tumors with or without mutations in the TSHR gene. Analysis by means of CD31 and D2-40 immunostaining showed in AFTN an increased number of hematic, but not lymphatic, vessels in parallel with an enhanced proliferation rate shown by increased Ki67 staining. Quantitative RT-PCR analysis revealed an increase of VEGF, VEGFR1 and 2, PDGF-A, PDGF-B, and eNOS expression in tumor versus normal tissues. Also, higher transcript levels of NIS, TPO, and Tg were detected. Comparison of the two subgroups of samples revealed only few differences in the expression of the genes examined. In conclusion, these data demonstrate an increased expression of angiogenesis-related factors associated with an enhanced proliferation of hematic, but not lymphatic, vessels in AFTNs. In this context, the presence of TSHR mutations may only slightly influence the expression of pro-angiogenic growth factors.
Literatur
1.
Zurück zum Zitat R.S. Bahn Chair, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association, American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6) 593–646 (2011) Erratum in: Thyroid 21(10) 1169 (2011) R.S. Bahn Chair, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association, American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21(6) 593–646 (2011) Erratum in: Thyroid 21(10) 1169 (2011)
2.
Zurück zum Zitat D. Russo, F. Arturi, E. Chiefari, S. Filetti, Molecular insights into TSH receptor abnormality and thyroid disease. J. Endocrinol. Invest. 20(1), 36–47 (1997)PubMed D. Russo, F. Arturi, E. Chiefari, S. Filetti, Molecular insights into TSH receptor abnormality and thyroid disease. J. Endocrinol. Invest. 20(1), 36–47 (1997)PubMed
3.
Zurück zum Zitat A. Hébrant, W.C. van Staveren, C. Maenhaut, J.E. Dumont, J. Leclère, Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur. J. Endocrinol. 164(1), 1–9 (2011)PubMedCrossRef A. Hébrant, W.C. van Staveren, C. Maenhaut, J.E. Dumont, J. Leclère, Genetic hyperthyroidism: hyperthyroidism due to activating TSHR mutations. Eur. J. Endocrinol. 164(1), 1–9 (2011)PubMedCrossRef
4.
Zurück zum Zitat F. Arturi, D. Scarpelli, A. Coco, R. Sacco, R. Bruno, S. Filetti, D. Russo, TSH receptor mutations and thyroid hyperfunctioning adenomas 10 years after their first discovery: unresolved questions. Thyroid 13(4), 341–343 (2003)PubMedCrossRef F. Arturi, D. Scarpelli, A. Coco, R. Sacco, R. Bruno, S. Filetti, D. Russo, TSH receptor mutations and thyroid hyperfunctioning adenomas 10 years after their first discovery: unresolved questions. Thyroid 13(4), 341–343 (2003)PubMedCrossRef
5.
Zurück zum Zitat D. Russo, M.G. Wong, G. Costante, E. Chiefari, P.A. Treseler, F. Arturi, S. Filetti, O.H. Clark, A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 9(1), 13–17 (1999)PubMedCrossRef D. Russo, M.G. Wong, G. Costante, E. Chiefari, P.A. Treseler, F. Arturi, S. Filetti, O.H. Clark, A Val 677 activating mutation of the thyrotropin receptor in a Hürthle cell thyroid carcinoma associated with thyrotoxicosis. Thyroid 9(1), 13–17 (1999)PubMedCrossRef
6.
Zurück zum Zitat D. Russo, C. Betterle, F. Arturi, E. Chiefari, M.E. Girelli, S. Filetti, A novel mutation in the thyrotropin receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J. Clin. Endocrinol. Metab. 85(11), 4238–4242 (2000)PubMedCrossRef D. Russo, C. Betterle, F. Arturi, E. Chiefari, M.E. Girelli, S. Filetti, A novel mutation in the thyrotropin receptor gene causing loss of TSH binding but constitutive receptor activation in a family with resistance to TSH. J. Clin. Endocrinol. Metab. 85(11), 4238–4242 (2000)PubMedCrossRef
7.
Zurück zum Zitat N. Garcia de la Torre, I. Buley, J.A.H. Wass, H.E. Turner, Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviour. Endocr. Relat. Cancer 13(3), 931–944 (2006)PubMedCrossRef N. Garcia de la Torre, I. Buley, J.A.H. Wass, H.E. Turner, Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumor behaviour. Endocr. Relat. Cancer 13(3), 931–944 (2006)PubMedCrossRef
8.
Zurück zum Zitat P. Viacava, G. Bocci, M. Tonnacchera, G. Fanelli, M. De Servi, P. Agretti, E. Berti, O. Goletti, P. Aretini, M.L. Resta, G. Bevilacqua, A.G. Naccarato, Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 17(3), 191–197 (2007)PubMedCrossRef P. Viacava, G. Bocci, M. Tonnacchera, G. Fanelli, M. De Servi, P. Agretti, E. Berti, O. Goletti, P. Aretini, M.L. Resta, G. Bevilacqua, A.G. Naccarato, Markers of cell proliferation, apoptosis, and angiogenesis in thyroid adenomas: a comparative immunohistochemical and genetic investigation of functioning and nonfunctioning nodules. Thyroid 17(3), 191–197 (2007)PubMedCrossRef
9.
Zurück zum Zitat M. Eszlinger, K. Krohn, R. Paschke, Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J. Clin. Endocrinol. Metab. 86(10), 4834–4842 (2001)PubMedCrossRef M. Eszlinger, K. Krohn, R. Paschke, Complementary DNA expression array analysis suggests a lower expression of signal transduction proteins and receptors in cold and hot thyroid nodules. J. Clin. Endocrinol. Metab. 86(10), 4834–4842 (2001)PubMedCrossRef
10.
Zurück zum Zitat M. Capezzone, E. Morabito, P. Belletti, P. Giannasio, D. De Sanctis, R. Bruno, Increasing incidence of thyroid cancer in Basilicata: an Italian study. J. Endocrinol. Invest. 30(6), 507–512 (2007)PubMed M. Capezzone, E. Morabito, P. Belletti, P. Giannasio, D. De Sanctis, R. Bruno, Increasing incidence of thyroid cancer in Basilicata: an Italian study. J. Endocrinol. Invest. 30(6), 507–512 (2007)PubMed
11.
Zurück zum Zitat D. Russo, S. Bulotta, R. Bruno, F. Arturi, P. Giannasio, M. Derwahl, J.M. Bidart, M. Schlumberger, S. Filetti, Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur. J. Endocrinol. 145(5), 591–596 (2001)PubMedCrossRef D. Russo, S. Bulotta, R. Bruno, F. Arturi, P. Giannasio, M. Derwahl, J.M. Bidart, M. Schlumberger, S. Filetti, Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur. J. Endocrinol. 145(5), 591–596 (2001)PubMedCrossRef
12.
Zurück zum Zitat D. Russo, G. Costante, R. Bruno, M. Sponziello, G. Tamburrano, M. Dima, R. Sacco, L. Giacomelli, C. Durante, S. Filetti, TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. Endocrine 40(3), 492–494 (2011)PubMedCrossRef D. Russo, G. Costante, R. Bruno, M. Sponziello, G. Tamburrano, M. Dima, R. Sacco, L. Giacomelli, C. Durante, S. Filetti, TSH receptor extracellular region mutations in thyroid functioning nodules: further evidence for the functional role of this region in the receptor activation. Endocrine 40(3), 492–494 (2011)PubMedCrossRef
13.
Zurück zum Zitat M.L. Sponziello, R. Bruno, C. Durante, M. D’Agostino, R. Corradino, P. Giannasio, E. Ciociola, E. Ferretti, M. Maranghi, A. Verrienti, G. De Toma, S. Filetti, D. Russo, Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm. Metab. Res. 43(1), 22–25 (2011)PubMedCrossRef M.L. Sponziello, R. Bruno, C. Durante, M. D’Agostino, R. Corradino, P. Giannasio, E. Ciociola, E. Ferretti, M. Maranghi, A. Verrienti, G. De Toma, S. Filetti, D. Russo, Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression. Horm. Metab. Res. 43(1), 22–25 (2011)PubMedCrossRef
14.
Zurück zum Zitat K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 25(4), 402–408 (2001)PubMedCrossRef K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 25(4), 402–408 (2001)PubMedCrossRef
15.
Zurück zum Zitat C. Durante, G. Tallini, E. Puxeddu, M. Sponziello, S. Moretti, C. Logorio, A. Cavaliere, K.J. Rhoden, A. Verrienti, M. Maranghi, L. Giacomelli, D. Russo, S. Filetti, BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur. J. Endocrinol. 165(3), 455–463 (2011)PubMedCrossRef C. Durante, G. Tallini, E. Puxeddu, M. Sponziello, S. Moretti, C. Logorio, A. Cavaliere, K.J. Rhoden, A. Verrienti, M. Maranghi, L. Giacomelli, D. Russo, S. Filetti, BRAF V600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. Eur. J. Endocrinol. 165(3), 455–463 (2011)PubMedCrossRef
16.
Zurück zum Zitat G. Tallini, G. Garcia-Rostan, A. Herrero, D. Zelterman, G. Viale, S. Bosari, M.L. Carcangiu, Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am. J. Surg. Pathol. 23(6), 678–685 (1999)PubMedCrossRef G. Tallini, G. Garcia-Rostan, A. Herrero, D. Zelterman, G. Viale, S. Bosari, M.L. Carcangiu, Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am. J. Surg. Pathol. 23(6), 678–685 (1999)PubMedCrossRef
17.
Zurück zum Zitat M. D’Agostino, P. Voce, M. Celano, M. Sponziello, S. Moretti, V. Maggisano, A. Verrienti, C. Durante, S. Filetti, E. Puxeddu, D. Russo, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22(2), 138–144 (2012)PubMedCrossRef M. D’Agostino, P. Voce, M. Celano, M. Sponziello, S. Moretti, V. Maggisano, A. Verrienti, C. Durante, S. Filetti, E. Puxeddu, D. Russo, Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. Thyroid 22(2), 138–144 (2012)PubMedCrossRef
19.
Zurück zum Zitat K.L. Kojic, S.L. Kojic, S.M. Wiseman, Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev. Anticancer Ther. 12(3), 345–357 (2012)PubMedCrossRef K.L. Kojic, S.L. Kojic, S.M. Wiseman, Differentiated thyroid cancers: a comprehensive review of novel targeted therapies. Expert Rev. Anticancer Ther. 12(3), 345–357 (2012)PubMedCrossRef
20.
Zurück zum Zitat G. Viglietto, A. Romano, G. Manzo, G. Chiappetta, I. Paoletti, D. Califano, M.G. Galati, V. Mauriello, P. Bruni, C.T. Lago, A. Fusco, M.G. Persico, Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15(22), 2687–2698 (1997)PubMedCrossRef G. Viglietto, A. Romano, G. Manzo, G. Chiappetta, I. Paoletti, D. Califano, M.G. Galati, V. Mauriello, P. Bruni, C.T. Lago, A. Fusco, M.G. Persico, Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization. Oncogene 15(22), 2687–2698 (1997)PubMedCrossRef
21.
Zurück zum Zitat A. Jebreel, J. England, K. Bedford, J. Murphy, L. Karsai, S. Atkin, Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int. J. Exp. Pathol. 88(4), 271–277 (2007)PubMedCrossRef A. Jebreel, J. England, K. Bedford, J. Murphy, L. Karsai, S. Atkin, Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int. J. Exp. Pathol. 88(4), 271–277 (2007)PubMedCrossRef
22.
Zurück zum Zitat K. Sato, K. Yamazaki, K. Shizume, Y. Kanaji, T. Obara, K. Ohsumi, H. Demura, S. Yamaguchi, M. Shibuya, Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J. Clin. Invest. 96(3), 1295–1302 (1995)PubMedCrossRef K. Sato, K. Yamazaki, K. Shizume, Y. Kanaji, T. Obara, K. Ohsumi, H. Demura, S. Yamaguchi, M. Shibuya, Stimulation by thyroid-stimulating hormone and Grave’s immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J. Clin. Invest. 96(3), 1295–1302 (1995)PubMedCrossRef
23.
Zurück zum Zitat S. Hoffmann, L.C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, A. Zielke, Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J. Clin. Endocrinol. Metab. 89(12), 6139–6145 (2004)PubMedCrossRef S. Hoffmann, L.C. Hofbauer, V. Scharrenbach, A. Wunderlich, I. Hassan, S. Lingelbach, A. Zielke, Thyrotropin (TSH)-induced production of vascular endothelial growth factor in thyroid cancer cells in vitro: evaluation of TSH signal transduction and of angiogenesis-stimulating growth factors. J. Clin. Endocrinol. Metab. 89(12), 6139–6145 (2004)PubMedCrossRef
24.
Zurück zum Zitat S. Deleu, Y. Allory, A. Radulescu, I. Pirson, N. Carrasco, B. Corvilain, I. Salmon, B. Franc, J.E. Dumont, J. Van Sande, C. Maenhaut, Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology. Thyroid 10(2) 131–140 (2000). Erratum in: Thyroid 2001 Jun; 11(6): following 609 S. Deleu, Y. Allory, A. Radulescu, I. Pirson, N. Carrasco, B. Corvilain, I. Salmon, B. Franc, J.E. Dumont, J. Van Sande, C. Maenhaut, Characterization of autonomous thyroid adenoma: metabolism, gene expression, and pathology. Thyroid 10(2) 131–140 (2000). Erratum in: Thyroid 2001 Jun; 11(6): following 609
25.
Zurück zum Zitat F.T. Hall, J.L. Freeman, S.L. Asa, D.G. Jackson, N.J. Beasley, Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 129(7), 716–719 (2003)PubMedCrossRef F.T. Hall, J.L. Freeman, S.L. Asa, D.G. Jackson, N.J. Beasley, Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 129(7), 716–719 (2003)PubMedCrossRef
26.
Zurück zum Zitat I.M. Colin, E. Nava, D. Toussaint, D.M. Maiter, M.F. van Denhove, T.F. Lüscher, J.M. Ketelslegers, J.F. Denef, J.L. Jameson, Expression of nitric oxide synthase isoforms in the thyroid gland: evidence for a role of nitric oxide in vascular control during goiter formation. Endocrinology 136(12), 5283–5290 (1995)PubMedCrossRef I.M. Colin, E. Nava, D. Toussaint, D.M. Maiter, M.F. van Denhove, T.F. Lüscher, J.M. Ketelslegers, J.F. Denef, J.L. Jameson, Expression of nitric oxide synthase isoforms in the thyroid gland: evidence for a role of nitric oxide in vascular control during goiter formation. Endocrinology 136(12), 5283–5290 (1995)PubMedCrossRef
27.
Zurück zum Zitat I.M. Colin, P. Kopp, J. Zbären, A. Häberli, W.E. Grizzle, J.L. Jameson, Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroidism. Eur. J. Endocrinol. 136(6), 649–655 (1997)PubMedCrossRef I.M. Colin, P. Kopp, J. Zbären, A. Häberli, W.E. Grizzle, J.L. Jameson, Expression of nitric oxide synthase III in human thyroid follicular cells: evidence for increased expression in hyperthyroidism. Eur. J. Endocrinol. 136(6), 649–655 (1997)PubMedCrossRef
28.
Zurück zum Zitat J.E. Donckier, L. Michel, M. Delos, X. Havaux, R. Van Beneden, Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 64(6), 703–710 (2006)CrossRef J.E. Donckier, L. Michel, M. Delos, X. Havaux, R. Van Beneden, Interrelated overexpression of endothelial and inducible nitric oxide synthases, endothelin-1 and angiogenic factors in human papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 64(6), 703–710 (2006)CrossRef
29.
Zurück zum Zitat M. Celano, F. Arturi, I. Presta, R. Bruno, D. Scarpelli, M.G. Calvagno, C. Cristofaro, S. Bulotta, P. Giannasio, R. Sacco, S. Filetti, D. Russo, Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol. Cell. Endocrinol. 203(1–2), 129–135 (2003)PubMedCrossRef M. Celano, F. Arturi, I. Presta, R. Bruno, D. Scarpelli, M.G. Calvagno, C. Cristofaro, S. Bulotta, P. Giannasio, R. Sacco, S. Filetti, D. Russo, Expression of adenylyl cyclase types III and VI in human hyperfunctioning thyroid nodules. Mol. Cell. Endocrinol. 203(1–2), 129–135 (2003)PubMedCrossRef
30.
Zurück zum Zitat L. Persani, A. Lania, L. Alberti, R. Romoli, G. Mantovani, S. Filetti, A. Spada, M. Conti, Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J. Clin. Endocrinol. Metab. 85(8), 2872–2878 (2000)PubMedCrossRef L. Persani, A. Lania, L. Alberti, R. Romoli, G. Mantovani, S. Filetti, A. Spada, M. Conti, Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas. J. Clin. Endocrinol. Metab. 85(8), 2872–2878 (2000)PubMedCrossRef
31.
Zurück zum Zitat A. Brunetti, E. Chiefari, S. Filetti, D. Russo, The cyclic AMP response elements binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. Endocrinology 141(2), 722–730 (2000)PubMedCrossRef A. Brunetti, E. Chiefari, S. Filetti, D. Russo, The cyclic AMP response elements binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. Endocrinology 141(2), 722–730 (2000)PubMedCrossRef
32.
Zurück zum Zitat F. Arturi, C. Capula, E. Chiefari, S. Filetti, D. Russo, Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Exp. Clin. Endocrinol. Diabetes 106(3), 234–236 (1998)PubMedCrossRef F. Arturi, C. Capula, E. Chiefari, S. Filetti, D. Russo, Thyroid hyperfunctioning adenomas with and without Gsp/TSH receptor mutations show similar clinical features. Exp. Clin. Endocrinol. Diabetes 106(3), 234–236 (1998)PubMedCrossRef
33.
Zurück zum Zitat E. Puxeddu, S. Romagnoli, M.E. Dottorini, Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23(1), 13–21 (2011)PubMedCrossRef E. Puxeddu, S. Romagnoli, M.E. Dottorini, Targeted therapies for advanced thyroid cancer. Curr. Opin. Oncol. 23(1), 13–21 (2011)PubMedCrossRef
34.
Zurück zum Zitat B. Corvilain, J. Van Sande, J.E. Dumont, G. Vassart, Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. (Oxf.) 55(2), 143–158 (2001) B. Corvilain, J. Van Sande, J.E. Dumont, G. Vassart, Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. (Oxf.) 55(2), 143–158 (2001)
35.
Zurück zum Zitat E. Nishihara, C.R. Chen, Y. Mizutori-Sasai, M. Ito, S. Kubota, N. Amino, A. Miyauchi, B. Rapoport, Deletion of thyrotropin receptor residue Asp403 in a hyperfunctioning thyroid nodule provides insight into the role of the ectodomain in ligand-induced receptor activation. J. Endocrinol. Invest. 35(1), 49–53 (2012)PubMed E. Nishihara, C.R. Chen, Y. Mizutori-Sasai, M. Ito, S. Kubota, N. Amino, A. Miyauchi, B. Rapoport, Deletion of thyrotropin receptor residue Asp403 in a hyperfunctioning thyroid nodule provides insight into the role of the ectodomain in ligand-induced receptor activation. J. Endocrinol. Invest. 35(1), 49–53 (2012)PubMed
Metadaten
Titel
Increased expression of pro-angiogenic factors and vascularization in thyroid hyperfunctioning adenomas with and without TSH receptor activating mutations
verfasst von
Marilena Celano
Marialuisa Sponziello
Giovanni Tallini
Valentina Maggisano
Rocco Bruno
Mariavittoria Dima
Enrico Di Oto
Adriano Redler
Cosimo Durante
Rosario Sacco
Sebastiano Filetti
Diego Russo
Publikationsdatum
01.02.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9747-3

Weitere Artikel der Ausgabe 1/2013

Endocrine 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.